Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia

被引:139
作者
Esposito, Susanna [1 ]
Tagliabue, Claudia [1 ]
Picciolli, Irene [1 ]
Semino, Margherita [1 ]
Sabatini, Caterina [1 ]
Consolo, Silvia [1 ]
Bosis, Samantha [1 ]
Pinzani, Raffaella [1 ]
Principi, Nicola [1 ]
机构
[1] Univ Milan, Dept Maternal & Pediat Sci, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, I-20122 Milan, Italy
关键词
Antibiotic therapy; Antibiotics; Children; Community-acquired pneumonia; Pediatrics; Procalcitonin; RESPIRATORY-TRACT INFECTIONS; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; ERYTHROCYTE SEDIMENTATION-RATE; SERUM PROCALCITONIN; PNEUMOCOCCAL PNEUMONIA; BACTERIAL PNEUMONIA; CHILDREN; INTERLEUKIN-6; MULTICENTER;
D O I
10.1016/j.rmed.2011.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to evaluate the use of an algorithm based on a procalcitonin (PCT) cut-off value as a means of guiding antibiotic therapy, 319 hospitalised children with uncomplicated community-acquired pneumonia (CAP) were randomised 1:1 to be treated on the basis of the algorithm or in accordance with standard guidelines. The children in the PCT group did not receive antibiotics if their PCT level upon admission was <0.25 ng/mL, and those receiving antibiotics from the time of admission were treated until their PCT level was >0.25 ng/mL. The final analysis was based on 155 patients in the PCT group and 155 in the control group. In comparison with the controls, the PCT group received significantly fewer antibiotic prescriptions (85.8% vs 100%; p < 0.05), were exposed to antibiotics for a shorter time (5.37 vs 10.96 days; p < 0.05), and experienced fewer antibiotic-related adverse events (3.9% vs 25.2%; p < 0.05), regardless of CAP severity. There was no significant between-group difference in recurrence of respiratory symptoms and new antibiotic prescription in the month following enrollment. The results of this first prospective study using a PCT cut-off value to guide antibiotic therapy for pediatric CAP showed that this approach can significantly reduce antibiotic use and antibiotic-related adverse events in children with uncomplicated disease. However, because the study included mainly children with mild to moderate CAP and the risk of the use of the algorithm-based approach was not validated in a relevant number of severe cases, further studies are needed before it can be used in routine clinical practice. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1939 / 1945
页数:7
相关论文
共 50 条
[41]   Clinical usefulness of serum procalcitonin to distinguish between viral pneumonia and Mycoplasma pneumonia in children: A multicenter, cross-sectional study [J].
Kim, Sungmin ;
Hur, Gye ;
Sung, Myong Soon ;
Baek, Hey-Sung ;
Yoon, Jung Won ;
Choi, Sun Hee ;
Sheen, Youn Ho ;
Han, Man Yong .
ALLERGY ASTHMA & RESPIRATORY DISEASE, 2019, 7 (01) :22-27
[42]   Diagnostic accuracy of procalcitonin for bacterial pneumonia in children - a systematic review and meta-analysis [J].
Tsou, Po-Yang ;
Rafael, John ;
Ma, Yu-Kun ;
Wang, Yu-Hsun ;
Raj, Shekhar ;
Encalada, Santiago ;
Deanehan, Julia K. .
INFECTIOUS DISEASES, 2020, 52 (10) :683-697
[43]   Procalcitonin Guided Antibiotic Stewardship [J].
Kiya, Girum Tesfaye ;
Asefa, Elsah Tegene ;
Abebe, Gemeda ;
Mekonnen, Zeleke .
BIOMARKER INSIGHTS, 2024, 19
[44]   The remaining unsolved problems for rational antibiotic therapy use in pediatric community-acquired pneumonia [J].
Esposito, Susanna ;
Argentiero, Alberto ;
Rebecchi, Francesca ;
Fainardi, Valentina ;
Pisi, Giovanna ;
Principi, Nicola .
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (04) :497-505
[45]   Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review [J].
Kim, Jong Hun .
INFECTION AND CHEMOTHERAPY, 2022, 54 (04) :610-620
[46]   Impact of Pharmacist-Led Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Pneumonia [J].
Subedi, Bibidh ;
Louzon, Patricia ;
Zappas, Kristie ;
Onyia, Wilfred ;
DeBoer, Kevin .
HOSPITAL PHARMACY, 2020, 55 (03) :204-210
[47]   Impact of Viral Radiographic Features on Antibiotic Treatment for Pediatric Pneumonia [J].
Geanacopoulos, Alexandra T. ;
Lipsett, Susan C. ;
Hirsch, Alexander W. ;
Monuteaux, Michael C. ;
Neuman, Mark, I .
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2022, 11 (05) :207-213
[48]   Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study [J].
Stolz, D. ;
Smyrnios, N. ;
Eggimann, P. ;
Pargger, H. ;
Thakkar, N. ;
Siegemund, M. ;
Marsch, S. ;
Azzola, A. ;
Rakic, J. ;
Mueller, B. ;
Tamm, M. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (06) :1364-1375
[49]   Monitoring adherence to guidelines of antibiotic use in pediatric pneumonia: the MAREA study [J].
Di Pietro, Pasquale ;
Alberighi, Ornella Della Casa ;
Silvestri, Michela ;
Tosca, Maria Angela ;
Ruocco, Anna ;
Conforti, Giorgio ;
Rossi, Giovanni A. ;
Castagnola, Elio ;
Merlano, Maria Caterina ;
Zappettini, Simona ;
Renna, Salvatore .
ITALIAN JOURNAL OF PEDIATRICS, 2017, 43
[50]   Value of the Serum Procalcitonin Level to Guide Antimicrobial Therapy for Patients with Ventilator-Associated Pneumonia [J].
Luyt, Charles-Edouard ;
Combes, Alain ;
Trouillet, Jean-Louis ;
Chastre, Jean .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (02) :181-187